Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma.
van Lieshout L, van der Ploeg P, Wesseling-Rozendaal Y, van de Stolpe A, Bosch S, Lentjes-Beer M, Ottenheijm M, Meriaan A, Vos C, de Hullu J, Massuger L, Bekkers R, Piek J. van Lieshout L, et al. Among authors: van der ploeg p. Cancers (Basel). 2021 Oct 12;13(20):5101. doi: 10.3390/cancers13205101. Cancers (Basel). 2021. PMID: 34680250 Free PMC article.
Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-κB Pathway Activity: A Novel Approach to a Long-Standing Enigma.
van Lieshout L, van de Stolpe A, van der Ploeg P, Bowtell D, de Hullu J, Piek J. van Lieshout L, et al. Among authors: van der ploeg p. Cancers (Basel). 2020 Sep 18;12(9):2660. doi: 10.3390/cancers12092660. Cancers (Basel). 2020. PMID: 32961868 Free PMC article.
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE, Theelen PMM, van der Ploeg P, Westgeest HM, Boere IA, Thijs AMJ, Ottevanger PB, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ. Hendrikse CSE, et al. Among authors: van der ploeg p. Gynecol Oncol. 2023 Apr;171:83-94. doi: 10.1016/j.ygyno.2023.01.038. Epub 2023 Feb 24. Gynecol Oncol. 2023. PMID: 36841040 Free article. Review.
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
Hendrikse CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, Oosterkamp F, Theelen PMM, Lok CAR, de Hullu JA, Smedts HPM, Vos MC, Pijlman BM, Kooreman LFS, Bulten J, Lentjes-Beer MHFM, Bosch SL, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ. Hendrikse CSE, et al. Among authors: van der ploeg p. Cancer. 2023 May 1;129(9):1361-1371. doi: 10.1002/cncr.34661. Epub 2023 Mar 3. Cancer. 2023. PMID: 36867576 Free article.
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
van der Ploeg P, Hendrikse CS, Thijs AM, Westgeest HM, Smedts HP, Vos MC, Jalving M, Lok CA, Boere IA, van Ham MA, Ottevanger PB, Westermann AM, Mom CH, Lalisang RI, Lambrechts S, Bekkers RL, Piek JM. van der Ploeg P, et al. Heliyon. 2023 Dec 1;10(1):e23170. doi: 10.1016/j.heliyon.2023.e23170. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187310 Free PMC article.
17 results